Abstract
Vaults have been suggested to play a direct role in multidrug resistance (MDR) to anticancer drugs. The human major vault protein (MVP) also known as lung resistance-related protein (LRP) represents the predominant component of vaults that may be involved in the defense against xenobiotics. Here, we demonstrate that besides MDR-related cytostatics, also the non-MDR-related drug 5-fluorouracil (5-FU) was able to induce MVP mRNA and protein expression. Treatment with 5-FU amplified the binding activity and interaction of the transcription factor Y-box binding protein-1 (YB-1) with the Y-box of the human MVP gene promoter in a time-dependent manner. 5-FU also induced reporter expressions driven by a panel of newly generated MVP promoter deletion mutants. Interestingly, stably YB-1 overexpressing cell clones showed enhanced binding of YB-1 to the Y-box motif, associated with enhanced basal as well as 5-FU-inducible MVP promoter-driven reporter expressions. Moreover, transduction of YB-1 cDNA led to increased expression of endogenous MVP protein. Under physiological conditions, we observed a strong coexpression of MVP and YB-1 in human colon carcinoma specimen. In summary, our data demonstrate a direct involvement of YB-1 in controlling basal and 5-FU-induced MVP promoter activity. Therefore, YB-1 is directly linked to MVP-mediated drug resistance.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Asakuno K, Kohno K, Uchiumi T, Kubo T, Sato S, Isono M and Kuwano M . (1994). Biochem. Biophys. Res. Commun., 199, 1428–1435.
Bargou RC, Jürchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B and Royer HD . (1997). Nat. Med., 3, 447–450.
Berger W, Elbling L and Micksche M . (2000). Int. J. Cancer, 88, 293–300.
Cheng SH, Lam W, Lee ASK, Fung KP, Wu RSS and Fong WF . (2000). Toxicol. Appl. Pharmacol., 64, 134–142.
Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC and Colgan SP . (2002). Cancer Res., 62, 3387–3394.
Emre N, Raval-Fernandes S, Kickhoefer VA and Rome LH . (2004). Biochim. Biophys. Acta, 1678, 33–46.
Hasegawa SL, Doetsch PW, Hamilton KK, Martin AM, Okenquist SA, Lenz J and Boss JM . (1991). Nucl. Acids Res., 19, 4915–4920.
Holm PS, Bergmann S, Jürchott K, Lage H, Brand K, Ladhoff A, Mantwill K, Curiel DT, Dobbelstein M, Dietel M, Gänsbacher B and Royer HD . (2002). J. Biol. Chem., 277, 10427–10434.
Hu Y, Stephen AG, Cao J, Tanzer LR, Slapak CA, Harrison SD, Devanarayan V, Dantzig AH, Starling JJ, Rome LH and Moore RE . (2002). Int. J. Cancer, 97, 149–156.
Ise T, Nagatani G, Imamura T, Kato K, Takano H, Nomoto M, Izumi H, Ohmori H, Okamoto T, Ohga T, Uchiumi T, Kuwano M and Kohno K . (1999). Cancer Res., 59, 342–346.
Izquierdo MA, Scheffer GL, Flens MJ, Giaccone G, Broxterman HJ, Meijer CJ, van der Valk P and Scheper RJ . (1996a). Am. J. Pathol., 148, 877–887.
Izquierdo MA, Shoemaker RH, Flens MJ, Scheffer GL, Wu L, Prather TR and Scheper RJ . (1996b). Int. J. Cancer, 65, 230–237.
Janz M, Harbeck N, Dettmar P, Berger U, Schmidt A, Jürchott K, Schmitt M and Royer HD . (2002). Int. J. Cancer, 97, 278–282.
Jürchott K, Bergmann S, Stein U, Walther W, Janz M, Manni I, Piaggio G, Fietze E, Dietel M and Royer HD . (2003). J. Biol. Chem., 278, 27988–27996.
Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ and Rome LH . (1998). J. Biol. Chem., 273, 8971–8974.
Kitazono M, Sumizawa T, Takebayashi Y, Chen ZS, Furukawa T, Nagayama S, Tani A, Takao S, Aikou T and Akiyama S . (1999). J. Natl. Cancer Inst., 91, 1647–1653.
Kohno K, Sato S, Takano H, Matsuo K and Kuwano M . (1989). Biochem. Biophys. Res. Commun., 165, 1415–1421.
Kohno K, Izumi H, Uchiumi T, Ashizuka M and Kuwano M . (2003). BioEssays, 25, 691–698.
Komarov PG, Shtil AA, Holian O, Tee L, Buckingham L, Mechetner EB, Roninson IB and Coon JS . (1998). Oncol. Res., 10, 185–192.
Kumar A and Reddy EP . (2001). Gene, 270, 221–229.
Kuwano M, Uchiumi T, Hayakawa H, Ono M, Wada M, Izumi H and Kohno K . (2003). Cancer Sci., 94, 9–14.
Labialle S, Gayet L, Marthinet E, Rigal D and Baggetto LG . (2002). Biochem. Pharmacol., 64, 943–948.
Lange C, Walther W, Schwabe H and Stein U . (2000). Biochem. Biophys. Res. Commun., 278, 125–133.
Lasham A, Moloney S, Hale T, Homer C, Zhang YF, Murison JG, Braithwaite AW and Watson J . (2003). J. Biol. Chem., 278, 35516–35523.
Laurencot CM, Scheffer GL, Scheper RJ and Shoemaker RH . (1997). Int. J. Cancer, 72, 1021–1026.
Meijer GA, Schroeijers AB, Flens MJ, Meuwissen SG, van der Valk P, Baak JP and Scheper RJ . (1999). J. Clin. Pathol., 52, 450–454.
Mertens PR, Steinmann K, Alfonso-Jaume MA, En-Nia A, Sun Y and Lovett DH . (2002). J. Biol. Chem., 277, 24875–24882.
Meschini S, Marra M, Calcabrini A, Monti E, Gariboldi M, Dolfini E and Arancia G . (2002). Toxicol. In vitro, 16, 389–398.
Midgley R and Kerr D . (1999). Lancet, 353, 391–399.
Mossink MH, van Zon A, Scheper RJ, Sonneveld P and Wiemer EA . (2003). Oncogene, 22, 7458–7467.
Oda Y, Sakamoto A, Shinohara N, Ohga T, Uchiumi T, Kohno K, Tsuneyoshi M, Kuwano M and Iwamoto Y . (1998). Clin. Cancer Res., 4, 2273–2277.
Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M, Kuwano M and Kohno K . (1996). Cancer Res., 56, 4224–4228.
Ohga T, Uchiumi T, Makino Y, Koike K, Wada M, Kuwano M and Kohno K . (1998). J. Biol. Chem., 273, 5997–6000.
Okamoto T, Izumi H, Imamura T, Takano H, Ise T, Uchiumi T, Kuwano M and Kohno K . (2000). Oncogene, 19, 6194–6202.
Pohl G, Filipits M, Suchomel RW, Stranzl T, Depisch D and Pirker R . (1999). Anticancer Res., 19, 5051–5055.
Pohl G, Suchomel RW, Stranzl T, Depisch D, Stiglbauer W, Filipits M and Pirker R . (2001). Anticancer Res., 21, 201–204.
Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC and Scheper RJ . (1995). Nat. Med., 1, 578–582.
Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA and Scheper RJ . (2000). Curr. Opin. Oncol., 12, 550–556.
Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P, Meijer CJLM and Pinedo HM . (1993). Cancer Res., 53, 1475–1479.
Schneider J, Gonzalez-Roces S, Pollan M, Lucas R, Tejerina A, Martin M and Alba A . (2001). Breast Cancer Res., 3, 183–191.
Schroeijers AB, Scheffer GL, Reurs AW, Pijnenborg AC, Abbondanza C, Wiemer EA and Scheper RL . (2001). J. Histochem. Cytochem., 49, 1379–1385.
Scotto KW . (2003). Oncogene, 22, 7496–7511.
Shibao K, Takano H, Nakayama Y, Okazaki K, Nagata N, Izumi H, Uchiumi T, Kuwano M, Kohno K and Itoh H . (1999). Int. J. Cancer, 83, 732–737.
Stein U, Walther W, Laurencot CM, Scheffer GL, Scheper RJ and Shoemaker RH . (1997). J. Natl. Cancer Inst., 89, 807–813.
Stein U, Jürchott K, Walther W, Bergmann S, Schlag PM and Royer HD . (2001). J. Biol. Chem., 276, 28562–28569.
Stein U, Jürchott K, Schläfke M and Hohenberger P . (2002). J. Clin. Oncol., 20, 3282–3292.
Steiner E, Holzmann K, Pirker C, Elbling L, Micksche M and Berger W . (2004). Biochem. Biophys. Res. Commun., 317, 235–243.
Tebbutt NC, Cattell E, Midgley R, Cunningham D and Kerr D . (2002). Eur. J. Cancer, 38, 1000–1015.
Wyler B, Shao Y, Schneider E, Cianfriglia M, Scheper RJ, Frey BM, Gieseler F, Schmid T, Twentyman PR and Lehnert M . (1997). Br. J. Haematol., 97, 65–75.
Zhang YF, Homer C, Edwards SJ, Hananeia L, Lasham A, Royds J, Sheard P and Braithwaite AW . (2003). Oncogene, 22, 2782–2794.
Zijlstra JG, de Vries EG and Mulder NH . (1987). Cancer Res., 47, 1780–1784.
Acknowledgements
The YB-1 antibody was kindly provided by Karsten Jürchott, Humboldt-University, Berlin. We gratefully acknowledge the excellent technical assistance of Lieselotte Malcherek, Anke Kopacek, and Jutta Aumann.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stein, U., Bergmann, S., Scheffer, G. et al. YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene. Oncogene 24, 3606–3618 (2005). https://doi.org/10.1038/sj.onc.1208386
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208386
Keywords
This article is cited by
-
Holistic anti-tumor resistance mechanism of YBX1 and its potential as a chemoresistance target in pancreatic ductal adenocarcinoma
Holistic Integrative Oncology (2023)
-
Y-box binding protein 1 (YB-1) promotes gefitinib resistance in lung adenocarcinoma cells by activating AKT signaling and epithelial–mesenchymal transition through targeting major vault protein (MVP)
Cellular Oncology (2021)
-
Architecture of The Human Ape1 Interactome Defines Novel Cancers Signatures
Scientific Reports (2020)
-
Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway
BMC Cancer (2019)
-
Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-κB signaling pathway in human neuroblastoma SH-SY5Y cells
Molecular and Cellular Biochemistry (2017)